Zealand Pharma AS (OCSE:ZEAL) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:ZEAL Zealand Pharma AS OCSE:ZEAL
68 GF Score
Price kr280.90
GF Value kr12,309.31
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

OCSE:ZEAL
68GF Score
Zealand Pharma AS OCSE:ZEAL
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zealand Pharma AS (OCSE:ZEAL) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of kr280.90 is trading 97.7% below its estimated GF Value™ of kr12,309.31. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for OCSE:ZEAL:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: kr12,309.31 vs. price of kr280.90 (97.7% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the OCSE:ZEAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
68GF Score

Get the complete analysis for OCSE:ZEAL

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr280.90
Price
kr12,309.31
GF Value